[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE378109B - - Google Patents

Info

Publication number
SE378109B
SE378109B SE7206644A SE664472A SE378109B SE 378109 B SE378109 B SE 378109B SE 7206644 A SE7206644 A SE 7206644A SE 664472 A SE664472 A SE 664472A SE 378109 B SE378109 B SE 378109B
Authority
SE
Sweden
Application number
SE7206644A
Inventor
R L Brattsand
K G Claeson
Af Ekenstam B Thuresson
B A Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE378109(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SE7206644A priority Critical patent/SE378109B/xx
Application filed by Bofors Ab filed Critical Bofors Ab
Priority to IL42155A priority patent/IL42155A/en
Priority to ZA732955A priority patent/ZA732955B/xx
Priority to AU55253/73A priority patent/AU487812B2/en
Priority to DE2323215A priority patent/DE2323215C3/de
Priority to GB2219473A priority patent/GB1429922A/en
Priority to CY1013A priority patent/CY1013A/xx
Priority to ES414673A priority patent/ES414673A1/es
Priority to FI731542A priority patent/FI50631C/fi
Priority to US360051A priority patent/US3929768A/en
Priority to CH699973A priority patent/CH595400A5/xx
Priority to YU1291/73A priority patent/YU35896B/xx
Priority to DD170888A priority patent/DD104295A5/xx
Priority to DK277273AA priority patent/DK134783B/da
Priority to PL1973162650A priority patent/PL87765B1/pl
Priority to NO2059/73A priority patent/NO139640C/no
Priority to HUBO1438A priority patent/HU166680B/hu
Priority to AT436573A priority patent/AT328630B/de
Priority to FR7318125A priority patent/FR2185405B1/fr
Priority to NLAANVRAGE7306978,A priority patent/NL177493C/xx
Priority to BE131270A priority patent/BE799727A/xx
Priority to SU1923451A priority patent/SU470954A3/ru
Priority to CA171,785A priority patent/CA1002938A/en
Priority to CS3590A priority patent/CS178129B2/cs
Priority to JP5623373A priority patent/JPS5521760B2/ja
Publication of SE378109B publication Critical patent/SE378109B/xx
Priority to US05/629,389 priority patent/US3983233A/en
Priority to KE2970A priority patent/KE2970A/xx
Priority to HK491/79A priority patent/HK49179A/xx
Priority to NL930025C priority patent/NL930025I1/nl
Priority to NO1994013C priority patent/NO1994013I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7206644A 1972-05-19 1972-05-19 SE378109B (xx)

Priority Applications (30)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (xx) 1972-05-19 1972-05-19
IL42155A IL42155A (en) 1972-05-19 1973-05-01 16alpha,17alpha-alkylidenedioxy-11beta,21-dihydroxy-pregna-1,4-diene-3,20-diones their manufacture and preparations containing same
ZA732955A ZA732955B (en) 1972-05-19 1973-05-01 New steroids,processes for their manufacture and preparations containing same
AU55253/73A AU487812B2 (en) 1972-05-19 1973-05-04 New Steroids, processes for their manufacture and preparations containing same
DE2323215A DE2323215C3 (de) 1972-05-19 1973-05-09 Pregna-l,4-dien-ll-ol-3,20-dione, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
GB2219473A GB1429922A (en) 1972-05-19 1973-05-09 Steroid acetals processes for their manufacture and preparations containing them
CY1013A CY1013A (en) 1972-05-19 1973-05-09 Steroid acetals, processes for their manufacture and preparations containing them
ES414673A ES414673A1 (es) 1972-05-19 1973-05-11 Procedimiento para preparar esteroides.
US360051A US3929768A (en) 1972-05-19 1973-05-14 Steroids, processes for their manufacture and preparations containing same
FI731542A FI50631C (fi) 1972-05-19 1973-05-14 Menetelmä pregnadieenijohdannaisten valmistamiseksi.
CH699973A CH595400A5 (xx) 1972-05-19 1973-05-16
YU1291/73A YU35896B (en) 1972-05-19 1973-05-16 Process for obtaining steroids
DD170888A DD104295A5 (xx) 1972-05-19 1973-05-17
DK277273AA DK134783B (da) 1972-05-19 1973-05-17 Analogifremgangsmåde til fremstilling af 16alfa,17alfa-alkylidendioxypregna-1,4-dien-11beta,21-diol-3,20-dioner.
NO2059/73A NO139640C (no) 1972-05-19 1973-05-18 Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner
PL1973162650A PL87765B1 (xx) 1972-05-19 1973-05-18
CS3590A CS178129B2 (xx) 1972-05-19 1973-05-18
HUBO1438A HU166680B (xx) 1972-05-19 1973-05-18
AT436573A AT328630B (de) 1972-05-19 1973-05-18 Verfahren zur herstellung neuer steroide
FR7318125A FR2185405B1 (xx) 1972-05-19 1973-05-18
NLAANVRAGE7306978,A NL177493C (nl) 1972-05-19 1973-05-18 Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen.
BE131270A BE799727A (fr) 1972-05-19 1973-05-18 Nouveaux steroides physiologiquement actifs, et procede pour leur preparation.
SU1923451A SU470954A3 (ru) 1972-05-19 1973-05-18 Способ получени производных кортикостероидов
CA171,785A CA1002938A (en) 1972-05-19 1973-05-18 Steroids, processes for their manufacture and preparations containing same
JP5623373A JPS5521760B2 (xx) 1972-05-19 1973-05-19
US05/629,389 US3983233A (en) 1972-05-19 1975-11-06 Compositions and method of treating with stereoisomeric mixtures of 2-unsymmetrical 16,17-methylenedioxy steroids
KE2970A KE2970A (en) 1972-05-19 1979-06-20 New steriod acetals, process for their manufacture and preparations containing them
HK491/79A HK49179A (en) 1972-05-19 1979-07-19 New steroid acetals, processes for their manufacture and preparations containing them
NL930025C NL930025I1 (nl) 1972-05-19 1993-04-13 Werkwijze voor de bereiding van steroïden en werkwijze ter bereiding van een farmaceutisch preparaattegen ontstekingen
NO1994013C NO1994013I1 (no) 1972-05-19 1994-08-31 Budenosid/ 16¿, 17¿-alkyldendioksypregna-1,4-dien-3,20-dioner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (xx) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
SE378109B true SE378109B (xx) 1975-08-18

Family

ID=20269234

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7206644A SE378109B (xx) 1972-05-19 1972-05-19

Country Status (26)

Country Link
US (2) US3929768A (xx)
JP (1) JPS5521760B2 (xx)
AT (1) AT328630B (xx)
BE (1) BE799727A (xx)
CA (1) CA1002938A (xx)
CH (1) CH595400A5 (xx)
CS (1) CS178129B2 (xx)
CY (1) CY1013A (xx)
DD (1) DD104295A5 (xx)
DE (1) DE2323215C3 (xx)
DK (1) DK134783B (xx)
ES (1) ES414673A1 (xx)
FI (1) FI50631C (xx)
FR (1) FR2185405B1 (xx)
GB (1) GB1429922A (xx)
HK (1) HK49179A (xx)
HU (1) HU166680B (xx)
IL (1) IL42155A (xx)
KE (1) KE2970A (xx)
NL (2) NL177493C (xx)
NO (2) NO139640C (xx)
PL (1) PL87765B1 (xx)
SE (1) SE378109B (xx)
SU (1) SU470954A3 (xx)
YU (1) YU35896B (xx)
ZA (1) ZA732955B (xx)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170642A2 (en) * 1984-07-30 1986-02-05 Aktiebolaget Draco Liposomes containing steroid esters
EP0197018A1 (en) * 1985-04-04 1986-10-08 Aktiebolaget Draco 16,17-Acetal-substituted androstane-17-beta-carboxylic-acid esters, process for their preparation and pharmaceutical compound containing them
EP0232690A1 (en) * 1985-12-19 1987-08-19 Aktiebolaget Draco Novel 16,17-acetalsubstituted pregnane-21-oic acid derivatives, process for the preparation thereof and pharmaceutical preparation containing them
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24B1 (ro) * 1991-07-09 1994-05-31 Parfumerii Si Cosmetice Vioric Compozitie de substante odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
ES2107806T3 (es) * 1992-12-24 1997-12-01 Rhone Poulenc Rorer Ltd Nuevos esteroides.
NZ259596A (en) * 1993-01-08 1997-04-24 Astra Ab Sugar-substituted glucocorticosteroid and use in medicaments specific to the colon or ileum
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
WO2004033478A2 (en) * 2002-10-08 2004-04-22 Sepracor Inc. Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
NZ545748A (en) * 2003-08-29 2010-03-26 Ranbaxy Lab Ltd Isoxazoline derivatives as inhibitors of phosphodiesterase type-IV
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
CA2561315A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP2009512676A (ja) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
EP1948167A1 (en) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Compositions of phosphodiesterase type iv inhibitors
CA2622640A1 (en) * 2005-11-02 2007-05-18 Sicor Inc. Improved process for the preparation of ciclesonide
TWI374147B (en) 2006-01-27 2012-10-11 Sun Pharma Advance Res Company Ltd Novel 11β-hydroxyandrosta-4-ene-3-ones
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
UA95115C2 (xx) 2006-08-22 2011-07-11 Ранбакси Лабораториз Лимитед Інгібітори матриксних металопротеїназ$ингибиторы матриксных металлопротеиназ
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
KR20090069309A (ko) * 2006-09-22 2009-06-30 랜박시 래보러터리스 리미티드 포스포디에스터라제 타입-ⅳ의 저해제
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101674820B (zh) 2006-12-26 2013-09-25 药品循环公司 在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标志物的方法
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
EP1958639A1 (en) 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
ES2382715T3 (es) 2007-03-14 2012-06-12 Ranbaxy Laboratories Limited Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
US8796248B2 (en) * 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
CA2714653A1 (en) * 2008-03-13 2009-09-17 Farmabios S.P.A. Process for the preparation of pregnane derivatives
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布地奈德的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
BRPI1011220B1 (pt) 2009-05-29 2020-03-10 Pearl Therapeutics, Inc. Composição farmacêutica administrável a partir de um inalador de dose medida compreendendo um meio de suspensão compreendendo um propelente, duas ou mais espécies diferentes de partículas de agente ativo e uma ou mais espécies de partículas respiráveis em suspensão
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
DK3403654T3 (da) 2009-10-01 2019-08-26 Adare Dev I L P Oralt administrerede kortikosteroidsammensætninger
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン，インク． アロステリックキナーゼ阻害が関係する治療方法および組成物
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布地奈德的制备方法
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2755648B1 (en) 2011-09-13 2017-03-08 Pharmacyclics LLC Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013109214A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
CN104736535B (zh) 2012-08-24 2017-12-19 德州大学系统董事会 用于治疗疾病的hif活性的杂环调节剂
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
RU2660349C2 (ru) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Композиции и способы для лечения злокачественной опухоли
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CA2912927A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016120891A1 (en) 2015-01-30 2016-08-04 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
IL307357A (en) 2016-11-08 2023-11-01 Regeneron Pharma Steroids and their protein conjugates
US11491237B2 (en) 2017-05-18 2022-11-08 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
IL313068A (en) 2017-11-07 2024-07-01 Regeneron Pharma Hydrophilic linkers for drug-antibody conjugates
EP3706747A4 (en) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
MX2020006994A (es) 2018-01-08 2020-11-06 Regeneron Pharma Esteroides y conjugados de anticuerpos de los mismos.
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US20230108452A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
JP2024525567A (ja) 2021-07-09 2024-07-12 アストラゼネカ・ファーマシューティカルズ・リミテッド・パートナーシップ エアロゾル薬物送達のための組成物、方法および系
CN118414148A (zh) 2021-12-20 2024-07-30 阿斯利康(瑞典)有限公司 用于气溶胶药物递送的组合物、方法和系统
WO2024049931A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (xx) * 1971-10-08 1973-06-25

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170642A2 (en) * 1984-07-30 1986-02-05 Aktiebolaget Draco Liposomes containing steroid esters
EP0170642A3 (en) * 1984-07-30 1986-10-29 Aktiebolaget Draco Liposomes containing steroid esters
US4693999A (en) * 1984-07-30 1987-09-15 Aktiebolaget Draco Liposomes containing steroid esters
EP0197018A1 (en) * 1985-04-04 1986-10-08 Aktiebolaget Draco 16,17-Acetal-substituted androstane-17-beta-carboxylic-acid esters, process for their preparation and pharmaceutical compound containing them
EP0355859A1 (en) * 1985-04-04 1990-02-28 Aktiebolaget Draco Process for the preparation of intermediates for 11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-3,20-dione 16-alpha,17-alpha-acetals and 21-esters thereof
US4950659A (en) * 1985-04-04 1990-08-21 Aktiebolaget Draco 16,17-acetalsubstituted androstane-17β-carboxylic acid esters prossessing high binding affinity to the glucocorticosteroid receptor
EP0232690A1 (en) * 1985-12-19 1987-08-19 Aktiebolaget Draco Novel 16,17-acetalsubstituted pregnane-21-oic acid derivatives, process for the preparation thereof and pharmaceutical preparation containing them
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives

Also Published As

Publication number Publication date
ATA436573A (de) 1975-06-15
DE2323215C3 (de) 1978-03-30
NO139640B (no) 1979-01-08
NL930025I1 (nl) 1993-06-01
ZA732955B (en) 1974-04-24
IL42155A (en) 1977-06-30
IL42155A0 (en) 1973-07-30
DK134783C (xx) 1977-06-06
DK134783B (da) 1977-01-17
NO1994013I1 (no) 1994-08-31
KE2970A (en) 1979-07-20
US3929768A (en) 1975-12-30
JPS4941378A (xx) 1974-04-18
NL177493B (nl) 1985-05-01
GB1429922A (en) 1976-03-31
DE2323215A1 (de) 1973-11-29
AU5525373A (en) 1974-11-07
YU129173A (en) 1981-02-28
HK49179A (en) 1979-07-27
FR2185405B1 (xx) 1976-12-31
SU470954A3 (ru) 1975-05-15
FI50631C (fi) 1976-05-10
AT328630B (de) 1976-03-25
CA1002938A (en) 1977-01-04
DD104295A5 (xx) 1974-03-05
DE2323215B2 (de) 1977-08-11
NL177493C (nl) 1985-10-01
NO139640C (no) 1979-04-18
ES414673A1 (es) 1976-07-01
CH595400A5 (xx) 1978-02-15
CY1013A (en) 1979-11-23
FI50631B (xx) 1976-02-02
JPS5521760B2 (xx) 1980-06-12
PL87765B1 (xx) 1976-07-31
HU166680B (xx) 1975-05-28
NL7306978A (xx) 1973-11-21
CS178129B2 (xx) 1977-08-31
YU35896B (en) 1981-08-31
US3983233A (en) 1976-09-28
FR2185405A1 (xx) 1974-01-04
BE799727A (fr) 1973-09-17

Similar Documents

Publication Publication Date Title
DK134783C (xx)
JPS5310261Y2 (xx)
JPS4922698A (xx)
JPS4967693A (xx)
JPS532684B2 (xx)
JPS4991055U (xx)
JPS4931853U (xx)
JPS4983913A (xx)
JPS5152585Y2 (xx)
FR2201400B1 (xx)
JPS4954627U (xx)
JPS4951452U (xx)
FR2173124A1 (xx)
CH574045A5 (xx)
CH562712A5 (xx)
CH569793A5 (xx)
CH570330A5 (xx)
CH570644B5 (xx)
CH566193A5 (xx)
CH566080A5 (xx)
CH564690A5 (xx)
CH564534A5 (xx)
CH572530A5 (xx)
CH563886A5 (xx)
CH562941A5 (xx)